| Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript |
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors, IR Jon Congleton - CEO Dave Rodman - Chief Medical Officer Adam Levy - CFO Conference Call Participants Michael DiFiore - Evercore ISI Richard Law - Goldman Sachs Seamus Fernandez - Guggenheim Rami Katkhuda - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Mineralys First Quarter 2025 Earnings Conference Call. At this time, all lines are in listen-only mode. |
seekingalpha.com |
2025-05-13 00:20:28 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update |
– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa. |
globenewswire.com |
2025-05-12 20:05:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference |
RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Bank of America Securities 2025 Health Care Conference being held in Las Vegas on May 12-15, 2025. |
globenewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 |
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025. |
globenewswire.com |
2025-05-05 20:05:00 |
Czytaj oryginał (ang.) |
| Carl Icahn Buys More Shares, and Tesla Insider Bucks the Selling Trend |
Insider buying has slowed considerably in the past week or so, due largely to the current first-quarter earnings reporting season. |
247wallst.com |
2025-05-01 12:45:02 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) |
– Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and progression – |
globenewswire.com |
2025-04-23 21:23:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) |
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile – |
globenewswire.com |
2025-03-29 16:30:00 |
Czytaj oryginał (ang.) |
| Insiders Make Huge Purchases of These 4 Biotech Stocks |
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations. |
247wallst.com |
2025-03-26 10:40:53 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET |
Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension |
globenewswire.com |
2025-03-25 10:00:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock |
RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the closing of the sale of an additional 1,944,444 shares of its common stock at a public offering price of $13.50 per share pursuant to the exercise in full of the underwriters' option to purchase additional shares in connection with Mineralys' recently completed public offering. After giving effect to the sale of these additional shares, the aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $201.2 million. All of the securities sold in the offering were sold by Mineralys. |
globenewswire.com |
2025-03-18 18:01:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo |
RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that data from the Phase 2 Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25), which is being held in Chicago on March 29-31, 2025. |
globenewswire.com |
2025-03-17 10:00:00 |
Czytaj oryginał (ang.) |
| Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session |
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday. |
benzinga.com |
2025-03-12 10:36:14 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock |
RADNOR, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten public offering of 12,962,962 shares of its common stock at a public offering price of $13.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $175.0 million. In addition, Mineralys has granted the underwriters a 30-day option to purchase up to an additional 1,944,444 shares of its common stock. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is expected to close on or about March 13, 2025, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2025-03-12 00:20:00 |
Czytaj oryginał (ang.) |
| Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts |
Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data release from Advance-HTN in March 2025 and phase 2 Explore-CKD trial results in Q2 2025. Financially, company has $198.2 million in cash but may need to raise funds soon, potentially diluting shareholders. |
seekingalpha.com |
2025-03-10 20:25:06 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Announces Proposed Public Offering of Common Stock |
RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. In addition, Mineralys expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. |
globenewswire.com |
2025-03-10 18:01:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate |
On Monday, Mineralys Therapeutics, Inc. MLYS released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials of lorundrostat for uncontrolled hypertension (uHTN) or resistant hypertension (rHTN). |
benzinga.com |
2025-03-10 15:50:08 |
Czytaj oryginał (ang.) |
| Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher |
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 700 points on Monday. |
benzinga.com |
2025-03-10 15:09:11 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics' blood pressure drug meets goal in trials |
Mineralys Therapeutics said on Monday its blood pressure drug, lorundrostat, met the main goal in late- and mid- stage trials. |
reuters.com |
2025-03-10 09:12:44 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension |
– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at week 6 – – Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction in systolic blood pressure, and an 11.7 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at end of treatment, week 12 – – Advance-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a highly statistically significant 7.9 mmHg placebo-adjusted reduction assessed by 24hr ABPM at end of treatment, week 12 – – Lorundrostat demonstrated a favorable safety and tolerability profile in both pivotal trials – – Full results from Advance-HTN to be presented on March 29, 2025, at the American College of Cardiology Scientific Sessions – – Conference call today at 8:00 a.m. ET – RADNOR, Pa. |
globenewswire.com |
2025-03-10 09:00:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET |
RADNOR, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar to announce topline results from its Launch-HTN and Advance-HTN pivotal trials on Monday, March 10, 2025, at 8:00 a.m. ET. |
globenewswire.com |
2025-03-07 18:01:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript |
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q4 2024 Results Conference Call February 12, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore ISI Rich Law - Goldman Sachs Annabel Samimy - Stifel Mohit Bansal - Wells Fargo Rami Khadkar - LifeSci Capital Matthew Caufield - H. C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the Mineralys Fourth Quarter and Full Year 2024 Earnings Conference Call. |
seekingalpha.com |
2025-02-12 15:38:04 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update |
– Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 – |
globenewswire.com |
2025-02-12 09:00:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025 |
RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2024, before the financial markets open on Wednesday, February 12, 2025. |
globenewswire.com |
2025-02-05 18:05:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension |
I believe Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. It should report more key pivotal clinical data this year. MLYS has several Phase 2 and 3 trials on Lorundrostat that could position it favorably for a potential FDA submission by late 2026 or sometime in 2027. According to the company's slides, Lorundrostat seems to have superior selectivity in some patients that reduces cortisol suppression and other side effects. |
seekingalpha.com |
2025-01-19 22:18:44 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript |
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore Richard Law - Goldman Sachs Annabel Samimy - Stifel Rami Katkhuda - LifeSci Capital Matthew Caufield - H.C. Wainright Operator Greetings. |
seekingalpha.com |
2024-11-12 00:00:07 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa. |
globenewswire.com |
2024-11-11 18:05:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics to Participate in Upcoming Investor Conferences |
RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences. |
globenewswire.com |
2024-11-05 18:05:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 |
RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024. |
globenewswire.com |
2024-11-04 18:05:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Inc Is Being Investigated For Securities Law Violations And Shareholders Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / October 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-21 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud |
LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-20 15:00:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Inc Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-19 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Investors To Take Part In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud |
LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-18 15:00:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics Inc Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-17 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Securities Fraud |
LOS ANGELES, CA / ACCESSWIRE / October 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-16 15:00:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / October 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-15 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Investors To Take Part In An Inquiry Into Mineralys Therapeutics Inc For Possible Securities Fraud |
LOS ANGELES, CA / ACCESSWIRE / October 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-14 15:00:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-13 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Securities Fraud |
LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-12 15:00:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / October 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-11 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Possible Securities Fraud |
LOS ANGELES, CA / ACCESSWIRE / October 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-10 15:00:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / October 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-09 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Possible Securities Fraud |
LOS ANGELES, CA / ACCESSWIRE / October 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-08 15:00:00 |
Czytaj oryginał (ang.) |
| Mineralys Therapeutics, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / October 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-07 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Possible Securities Fraud |
LOS ANGELES, CA / ACCESSWIRE / October 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-06 15:00:00 |
Czytaj oryginał (ang.) |